| 发明名称 |
Immunogenic compositions and a process for producing same |
| 摘要 |
The present invention provides a modified HIV envelope glycoprotein (Env) antigen or a lipid containing vehicle comprising same. The Env antigen comprises one of a second site suppressor mutation in residue 674 of the membrane proximal ectodomain region (MPER) of HIV gp41; a second site suppressor mutation which ablates a glycosylation site in the variable region (V1) region of gp120; or a second site suppressor mutation ablating a glycosylation site in the V1 region of gp120 and a second site suppressor mutation in residue 674 of the MPER of HIV gp41. It is preferred that the lipid containing vehicle is a HIVLP. |
| 申请公布号 |
US2016122395(A1) |
申请公布日期 |
2016.05.05 |
| 申请号 |
US201414776802 |
申请日期 |
2014.03.17 |
| 申请人 |
THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD |
发明人 |
DRUMMER Heidi;POUMBOURIOS Pantelis |
| 分类号 |
C07K14/005;C12N7/00;A61K39/21 |
主分类号 |
C07K14/005 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A modified HIV envelope glycoprotein (Env) antigen or a lipid containing vehicle comprising same wherein the Env antigen comprises one of:
(i) a second site suppressor mutation in residue 674 of the membrane proximal ectodomain region (MPER) of HIV gp41; (ii) a second site suppressor mutation which ablates a glycosylation site in the variable region (V1) region of gp120; or (iii) a second site suppressor mutation ablating a glycosylation site in the V1 region of gp120 and a second site suppressor mutation in residue 674 of the MPER of HIV gp41. |
| 地址 |
Melbourne, Victoria AU |
